Predictors of inactive disease and remission in children and young adults with juvenile idiopathic arthritis treated with etanercept
Authors' conclusion
In patients with JIA treated with etanercept, early responses to treatment in line with treat-to-target recommendations, younger age, HLA-B27+ status and lower disease activity at baseline were associated with clinically inactive disease and clinical remission.
Study context
- Population
- Patients with extended oligoarthritis (2–17 years), enthesitis-related arthritis or psoriatic arthritis (each 12–17 years) receiving etanercept
- Primary endpoint
- Predictors of CID (by JADAS and JIA-ACR response criteria) and CR (≥6 months of CID)
Methodological detailsphase 3b, 8-year extension study, multivariate stepwise logistic regression
- Phase 3b
- 8-year extension study
- Multivariate stepwise logistic regression
Primary result
As reported in the abstract
- Clinically inactive disease (CID) at any point
- Two-thirds of patients
- Clinical remission (CR) achieved
- 34-43%
Original publication
Predictors of inactive disease and remission in children and young adults with juvenile idiopathic arthritis treated with etanercept. Rheumatology (Oxford). Published 20 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →